TAVI Couple Cycling

EVOLUT TM TAVI NOW CE MARK APPROVED

FOR LOW RISK
SEVERE AORTIC STENOSIS
PATIENTS
Animation of Evolut Pro TAVR showing the three leaflets opening and closing into the aorta

Superior HEMODYNAMICS

Evolut™ TAVI is the only TAVI device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at one year.1

Learn about HEMODYNAMICS

Indications, Safety, and Warnings

SUPERIOR
EFFECTIVE ORIFICE AREAS (EOA)

EvolutTM TAVI
2.3 cm2 
vs.
SAVR 2.0 cm2

Blue up arrow with 15% text inside and text stating larger EOAs beneath it

SUPERIOR Gradients
 
 

EvolutTM TAVI
8.6 mm Hg
vs.
SAVR 11.2 mm Hg

Blue down arrow with 23% text inside and text stating lower gradients beneath it

SAFE and EFFECTIVE

As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1

A box with text that reads 5.3 percent TAVR and a second box next to it reads 6.7 percent SAVR

2-year Bayesian Analysis
n = 1,468

See More Low Risk Data

EvolutTM TAVI compared to SAVR

EvolutTM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR2

graph
Low Risk PPM Graph

Less Patient Prosthesis Mismatch.

Better Patient Outcomes.<sup>3,*</sup>

LEARN MORE ABOUT PPM

PATIENT PROSTHESIs
MIsMATCH MATTERS

Calculate your patient's risk of prosthesis mismatch.

PPM Calculator

EVOLUT™ TAVI BICUSPID INDICATION

Learn more

FASTER RETURN

TO AN

ACTIVE LIFE

 

EVOLUTTM TAVI SUPERIOR TO SAVR
in self-reported KCCQ measures at 30 days1

58% SHORTER HOSPITAL STAY
with TAVI procedures vs. SAVR procedures2

LOWER RATES OF HEART FAILURE REHOSPITALISATION
with EvolutTM TAVI vs. SAVR at one year2

Neem contact op voor meer informatie.

*Verplicht veld

Uw informatie zal worden verwerkt en beschermd overeenkomstig de bepalingen in onze privacyverklaring

Bekijk onze privacyverklaring

1. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.

2. Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.

3. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. J Am Coll Cardiol. Published online September 18, 2018.

*Severe PPM is associated with increased mortality and HF rehospitalizations at 1 year.